Get started
Author

Ian Ragan

TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2 H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates
2005 · John R. Atack, Keith A. Wafford, et al. · Journal of Pharmacology and Experimental Therapeutics · 190
Preclinical safety testing of monoclonal antibodies: the significance of species relevance
2007 · Kathryn Chapman, Nick Pullen, et al. · Nature Reviews Drug Discovery · 122
Opportunities for improving animal welfare in rodent models of epilepsy and seizures
2015 · Katie Lidster, John G. Jefferys, et al. · Journal of Neuroscience Methods · 118
PDF
Preclinical development of monoclonal antibodies
2009 · Kathryn Chapman, Nick Pullen, et al. · mAbs · 103
Consensus Document on European Brain Research
2011 · Monica Di Luca, Mary Baker, et al. · European Journal of Neuroscience · 71
PDF
7-(1,1-Dimethylethyl)-6-(2-ethyl-2 H -1,2,4- triazol-3-ylmethoxy)-3-(2-fluorophenyl)- 1,2,4-triazolo[4,3- b ]pyridazine: A Functionally Selective γ-Aminobutyric Acid A (GABA A ) α2/α3-Subtype Selective Agonist That Exhibits Potent Anxiolytic Activity but Is Not Sedating in Animal Models
2005 · Robert W. Carling, Andrew Madin, et al. · Journal of Medicinal Chemistry · 56
The future of non-human primate use in mAb development
2010 · Kathryn L. Chapman, Nick Pullen, et al. · Drug Discovery Today · 44
The Rise of Three Rs Centres and Platforms in Europe*
2022 · Winfried Neuhaus, Birgit Reininger-Gutmann, et al. · Alternatives to Laboratory Animals · 41
PDF
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
2016 · Kathryn Chapman, Akosua Adjei, et al. · mAbs · 39
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials
2014 · Fiona Sewell, Kathryn Chapman, et al. · Regulatory Toxicology and Pharmacology · 37
PDF
Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals
2021 · Elliot Lilley, Richard Isbrucker, et al. · Biologicals · 36
PDF
Steps towards the international regulatory acceptance of non-animal methodology in safety assessment
2017 · Fiona Sewell, John Doe, et al. · Regulatory Toxicology and Pharmacology · 36
PDF
Applying the 3Rs to non-human primate research: Barriers and solutions
2017 · Mark J. Prescott, Jan A. Langermans, et al. · Drug Discovery Today Disease Models · 31
PDF
Apolipoprotein E genotyping in Alzheimer's disease
1996 · G McKeith, C.M Morris, et al. · The Lancet · 30
Advancing the 3Rs in regulatory toxicology – Carcinogenicity testing: Scope for harmonisation and advancing the 3Rs in regulated sectors of the European Union
2014 · Erwin Annys, Richard Billington, et al. · Regulatory Toxicology and Pharmacology · 29
3-(1-Piperazinyl)-4,5-dihydro-1H-benzo[g]indazoles: high affinity ligands for the human dopamine D4 receptor with improved selectivity over ion channels
1998 · Ian Collins, Michael Rowley, et al. · Bioorganic & Medicinal Chemistry · 27
Determination of the cDNA sequence for the human mitochondrial 75‐kDa Fe–S protein of NADH‐coenzyme Q reductase
1991 · Wendy CHOW, Ian RAGAN, et al. · European Journal of Biochemistry · 27
New supporting data to guide the use of evident toxicity in acute oral toxicity studies (OECD TG 420)
2023 · Fiona Sewell, Ian Ragan, et al. · Regulatory Toxicology and Pharmacology · 25
A global initiative to refine acute inhalation studies through the use of ‘evident toxicity’ as an endpoint: Towards adoption of the fixed concentration procedure
2015 · Fiona Sewell, Ian Ragan, et al. · Regulatory Toxicology and Pharmacology · 24
The Current Status and Work of Three Rs Centres and Platforms in Europe*
2022 · Winfried Neuhaus, Birgit Reininger-Gutmann, et al. · Alternatives to Laboratory Animals · 22
PDF
Preclinical screening for antidepressant activity – shifting focus away from the Forced Swim Test to the use of translational biomarkers
2021 · Fiona Sewell, Ian Waterson, et al. · Regulatory Toxicology and Pharmacology · 22
PDF
Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop
2017 · Martijn W.P. Bruysters, Marie-Jeanne Schiffelers, et al. · Biologicals · 21
PDF
The vaccines consistency approach project: an EPAA initiative.
2015 · F De Mattia, C Hendriksen, et al. · PubMed · 20
Fatal combined defects in mitochondrial multienzyme complexes in two siblings
1992 · B. H. Robinson, W. Chow, et al. · European Journal of Pediatrics · 14
Evidence that the Major Primary Biliary Cirrhosis‐Specific Mitochondrial Autoantigen is a Subunit of Complex I of the Respiratory Chain
1988 · Å. FROSTELL, I. MENDEL‐HARTVIG, et al. · Scandinavian Journal of Immunology · 14
Works count: 31
Citation count: 1,222
H-index: 21
I10-index: 25
Year
Topic
Type